Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER_GOV 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 7 Non-Muscle Invasive Bladder Neoplasms 5 Recurrence 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Melanoma 1 Carcinoma in Situ 1

Interventions

Dexamethasone 64 Cyclophosphamide 35 pomalidomide 34 Lenalidomide 34 Rituximab 31 Bortezomib 30 venetoclax 28 fludarabine 27 Gemcitabine 21 carfilzomib 20 Paclitaxel 19 pembrolizumab 17 daratumumab 17 Cisplatin 16 Carboplatin 15 Calcium Dobesilate 14 Azacitidine 14 ibrutinib 12 Docetaxel 12 Cytarabine 12 obinutuzumab 11 Nivolumab 11 durvalumab 10 Injections 10 Doxorubicin 10 Bevacizumab 10 selinexor 9 cemiplimab 9 blinatumomab 9 Cetuximab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × BCG Vaccine × Clear all

NCT05037279 2026-03-20

EVER

Verity Pharmaceuticals Inc.

Phase 3 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡